VIJAY KUMAR GUPTA
@vijay.kumar.gupta.9282
Rajasthan
5+ Years of experience
SEBI Registration INH000020226VIJAY GUPTA ADVISORY™ SEBI REGD. RESEARCH ANALYST INH000020226 www.VijayGuptaAdvisory.com
Trade Ideas
1k
Opinions
972
Followers
117k
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 28th Sep
Balrampur Chini: Distillery momentum masks sugar crunch
BALRAMCHIN
Balrampur Chini Q1 revenue rose 6.1% to Rs 1,636.79 crore but profit crashed 14% to Rs 44.1 crore. Market cheers distillery surge, misses sugar collapse. Sugar PBIT fell to 3.16% margin from historical 8-10%, signaling permanent cane cost inflation. Distillery offset saved Q1; without it, results would crater. Sugar has structurally reset lower, not seasonal. Rs 900 crore PLA capex remains through FY28, depressing profit until FY28-29 profitability. Fed rate cuts on Sep 17 weaken global bioplastic demand, raising PLA pricing risk. Profit recovery hinges entirely on (1) sugar stabilizing amid global weakness and (2) PLA launching profitably. Distillery growth alone cannot sustain expansion; core business is structurally impaired.
Binary: if PLA launches profitably by FY28 and sugar stabilizes, profit targets Rs 80-100 crore by FY29. If sugar stays compressed and PLA disappoints, profit stagnates at Rs 40-50 crore through FY28. Entry 325; target 310. Exit if distillery PBIT turns negative or PLA commissioning delays past December 2026.
---DISCLOSURE---
This post is for informational and educational purposes. I do not hold [$BCML] at the time of writing. Please do your own research and consult a financial advisor before trading or investing. shared an insight ⚡️ 28th Sep
Zydus Q1: Revenue growth masks R&D margin reset strategy
ZYDUSLIFE
Zydus Lifesciences reported Q1 FY27 revenue surged 22% to Rs 80.2 billion, but net profit crashed 36% to Rs 940 crore (vs Rs 1,470 crore estimate), shocking markets. EBITDA margin compressed to 24.1%. Market reads collapse as execution failure; reality is deliberate R&D-led margin reset. Zydus is in strategic transition: building India formulations business (targeting mid-teens growth) and expanding US specialty generics pipeline (USFDA approvals accelerating). This capex + R&D investment is permanent, eating into near-term profit. Lower US export growth trajectory signals pricing pressure on legacy generics, but management is pivoting toward higher-margin specialty products and India bulk drugs. Profit miss reveals the cost: Q1 R&D spend rose sharply; manufacturing capex for India formulations expansion ongoing. Market prices 22% revenue growth as sustainable profit driver; it masks that profit sustainability depends entirely on pipeline ROI and India scaling success. Margin reset is structural, not cyclical—profit recovery requires new launch contribution and India formulations hitting 15%+ CAGR by FY28.
Binary: if USFDA approvals (Ascorbic Acid and others) deliver premium pricing and India formulations scale to 15%+ growth, FY28 margins recover to 26-27% and profit grows. If US specialty launches disappoint or India formulations stay single-digit, margins stay compressed at 23-24% and profit growth stalls. Entry below Rs 750; target Rs 720. Exit if India formulations guidance falls below 10% or Q2 EBITDA margin falls below 23.5%.
---DISCLOSURE---
This post is for informational and educational purposes. I do not hold [ZYDUSLIFE
] at the time of writing. Please do your own research and consult a financial advisor before trading or investing. shared an insight ⚡️ 28th Sep
Infosys Q1: AI growth masks wage inflation margin squeeze
INFY
Infosys reported Q1 FY27 profit up 12%, AI revenue surged to 8.2% of total revenue, and operating margin held 21.1%. Market reads AI narrative as structural re-rating; reality is margin resilience masking wage inflation and attrition crisis. Attrition jumped to 13%, highest in years, forcing management into wage-hike cycles to retain talent on AI-skilled projects. Headcount fell by 532 despite AI demand, signaling that price gains from AI services are being consumed by wage bills. Operating margin at 21.1% looks stable because AI commands 30-35% margins vs traditional services at 18-20%, but this mix benefit masks underlying wage pressure. Fed rate cuts on Sep 17 compound the headwind: stronger rupee eats into dollar-denominated revenue and forces rupee-denominated wage cuts to remain competitive. CEO transition adds execution risk as new leadership manages margin vs growth trade-off amid talent cost inflation. Market prices AI as margin-accretive; it's actually margin-neutral because wage hikes match price gains.
Binary: if attrition stabilizes below 12% and AI stays 10%+ of revenue, margin sustains 20-21% on pricing power and FX stabilizes. If attrition stays 13%+ and wage hikes accelerate 8-10% YoY while FX strengthens further, margins compress to 19-20% despite AI growth. Entry below Rs 3,000; target Rs 2,850. Exit if Q2 attrition rises above 13.5% or operating margin falls below 20.5%.
---DISCLOSURE---
This post is for informational and educational purposes. I do not hold [INFY
] at the time of writing. Please do your own research and consult a financial advisor before trading or investing.FAQ's
What are the top stock recommendations by VIJAY KUMAR GUPTA?
VIJAY KUMAR GUPTA regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include BALRAMCHIN, ZYDUSLIFE and INFY. Explore VIJAY KUMAR GUPTA's complete list of posts and trade views on their StockGro profile.
How can I follow VIJAY KUMAR GUPTA's latest investment insights?
You can follow VIJAY KUMAR GUPTA's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is VIJAY KUMAR GUPTA's investment strategy?
VIJAY KUMAR GUPTA follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has VIJAY KUMAR GUPTA been a SEBI-registered Research Analyst (RA)?
VIJAY KUMAR GUPTA has been a SEBI-registered Research Analyst and have 5+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see VIJAY KUMAR GUPTA's past performance and stock picks?
You can check VIJAY KUMAR GUPTA's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact VIJAY KUMAR GUPTA for stock market advice?
For stock market guidance from VIJAY KUMAR GUPTA, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is VIJAY KUMAR GUPTA's track record in predicting market movements?
VIJAY KUMAR GUPTA has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for VIJAY KUMAR GUPTA?
VIJAY KUMAR GUPTA is a SEBI-registered Research Analyst with the SEBI Registration INH000020226. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro